REVISION THERAPEUTICS
ReVision Therapeutics, Inc. develops drugs for the treatment of age-related macular degeneration diseases. Its product includes Fenretinide, an oral medication that reduces the accumulation of A2E in the retina, and slows down the growth of atrophic lesions, which precedes vision loss. The company was founded in 2010 and is based in San Diego, California.
REVISION THERAPEUTICS
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2010-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.revisiontherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
858-768-7860
Total Funding:
3.37 M USD
Technology used in webpage:
Amazon GoDaddy DNS YouTube AWS Global Accelerator
Similar Organizations
Anthos Therapeutics
Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Current Advisors List
Official Site Inspections
http://www.revisiontherapeutics.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ReVision Therapeutics"
reVision Therapeutics
Revising how medicines are developed and commercialized.See details»
ReVision Therapeutics - Crunchbase Company Profile
ReVision Therapeutics, Inc. develops drugs for the treatment of age-related macular degeneration diseases. Its product includes Fenretinide, an oral medication that reduces the accumulation of …See details»
ReVision Therapeutics - Crunchbase Company Profile
ReVision Therapeutics is a drug development company that provides ophthalmic medicine and products, and dry eye disease therapy.See details»
Investor Information — reVision Therapeutics
Aug 17, 2021 · reVision Therapeutics Inc. is a preclinical-stage pharmaceutical company pioneering ophthalmic therapies and dedicated to the repurposing, development, and …See details»
ReVision Therapeutics, Inc. - Drug pipelines, Patents, …
About reVision Therapeutics, Inc. reVision Therapeutics is a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative …See details»
reVision Therapeutics, Inc. | LinkedIn
ReVision Therapeutics, Inc. was founded in 2018 to develop medicines with high disease impact, and rapidly get those medicines to patients.See details»
About — reVision Therapeutics
Oct 4, 2023 · Develop ophthalmic products to treat inadequately met needs for high-impact diseases. Mitigate risk by repositioning existing products: we repurpose approved drugs and rescue shelved drugs. Reduce cost by …See details»
ReVision Therapeutics - Craft
ReVision Therapeutics is a biopharmaceutical company operating in the ophthalmology field. It develops a small-molecule drug for the treatment and prevention of dry age-related macular …See details»
reVision Therapeutics Announces US FDA Grant …
Oct 28, 2020 · reVision Therapeutics is a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare diseases....See details»
reVision Therapeutics - VentureRadar
ReVision Therapeutics develops high impact ophthalmic products to treat unmet or poorly-met disorders. reVision reduces risk and cost by repositioning products (repurposing approved …See details»
reVision Therapeutics Announces US FDA Grant of Rare …
ReVision Therapeutics is a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare diseases. …See details»
Scientific Advisory Board — reVision Therapeutics
Dr. Sullivan is the Founder, recent President, and current Chairman of the Board of Directors of the Tear Film & Ocular Surface Society (TFOS), a non-profit organization tasked to advance …See details»
Aequus and reVision to Collaborate on Stargardt Disease …
ReVision Therapeutics is a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare diseases. …See details»
REVISION THERAPEUTICS: Announces US FDA Grant of …
Nov 3, 2020 · reVision Therapeutics, Inc., a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular …See details»
Phase 2b Data Suggest ReVision's Oral Fenretinide (RT …
Oct 18, 2010 · ReVision Therapeutics Inc. is an ophthalmic biopharmaceutical company developing a novel small-molecule drug to slow the progression of the dry form of age-related …See details»
reVision Therapeutics Announces US FDA Grant of Rare …
ReVision Therapeutics is a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare diseases. …See details»
ReVision's Fenretinide (RT-101) Reduced Incidence of …
SAN DIEGO, Sept. 1 /PRNewswire/ -- ReVision Therapeutics Inc. today announced that data from a Phase 2b trial show that fenretinide (RT-101) reduced the incidence of choroidal …See details»
Mission Therapeutics – Deubiquitylating enzymes: multiple …
World-leading DUB platform translating scientific advances into transformative therapies. First-in-class small molecule DUB inhibitors developed in-house and with partners. Multiple in-house …See details»
REV-0100 - reVision Therapeutics
REV-0100 was awarded both Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) designation by the US Food and Drug Administration. REV-0100 works by reducing levels of a …See details»
Aequus and reVision to Collaborate on Stargardt Disease
Aug 17, 2021 · VANCOUVER, British Columbia and RIDGEWOOD, N.J., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) and …See details»